Clinical use of ZSCAN4 for telomere elongation in hematopoietic stem cells

Myers, Kasiani C., Davies, Stella M., Lutzko, Carolyn, Wahle, Robin, Grier, David D., Aubert, Geraldine, Norris, Kevin, Baird, Duncan M. ORCID: https://orcid.org/0000-0001-8408-5467, Koga, Minako, Ko, Akihiro C., Amano, Tomokazu, Amano, Misa, Yu, Hong and Ko, Minoru S.H. 2025. Clinical use of ZSCAN4 for telomere elongation in hematopoietic stem cells. NEJM Evidence 4 (3) 10.1056/EVIDoa2400252

Preview

PDF - Accepted Post-Print Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (5MB) | Preview

Abstract

Background Extremely short telomeres in patients with dyskeratosis congenita and related telomere biology disorders (TBDs) lead to premature cellular senescence and bone marrow failure. Zinc finger and SCAN domain-containing 4 (ZSCAN4) elongates telomeres by recombination. Methods We report a clinical study in which EXG34217, the term given for autologous CD34+ hematopoietic stem cells from patients with TBD exposed to a temperature-sensitive Sendai virus vector encoding human ZSCAN4 at 33°C for 24 hours, was infused into patients without preconditioning. Results Four patients were enrolled; two experienced successful CD34+ mobilization during the second mobilization attempt and underwent apheresis and EXG34217 infusion, with follow-up of 5 and 24 months (both ongoing). We observed telomere elongation (1.06- to 1.34-fold) in CD34+ cells ex vivo. In one patient, the treatment was associated with a change in the mean absolute neutrophil count (ANC) from 1.78×103 to 3.18×103 cells/μl; the lymphocyte subpopulation telomere length changed from 3.6 to 6.7 kb (50th percentile for age). In the other patient, the treatment was associated with a change in the lowest ANC from 0.6×103/μl to 1.2×103/μl; this has occurred in 5 months without the patient receiving prior intermittent low-dose granulocyte–colony-stimulating factor injections. During mobilization, all patients experienced mild to moderate bone pain or pain after line replacement, and one patient had a blood infection associated with fever and hypoxemia. After EXG34217 infusion, no acute safety issues were noted; in one patient mild to moderate long-term cardiac and pulmonary adverse events were noted; these were similar to symptoms of the patient’s underlying conditions. Conclusions Although definitive conclusions cannot be drawn from the two EXG34217-treated patients, these results warrant further investigation of CD34+ cells exposed to ZSCAN4 for treating TBDs. (Funded by Elixirgen Therapeutics; ClinicalTrials.gov number, NCT04211714.)

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Schools > Medicine
Publisher:	Massachusetts Medical Society
ISSN:	2766-5526
Date of First Compliant Deposit:	11 March 2025
Date of Acceptance:	10 January 2025
Last Modified:	04 Apr 2025 10:45
URI:	https://orca.cardiff.ac.uk/id/eprint/176791

Actions (repository staff only)

Edit Item